June 2010

Persistent Prurigo Nodularis Responsive to Initiation of Combination Therapy With Raltegravir

Author Affiliations

Author Affiliations: Department of Dermatology, University of California, San Francisco.


Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Dermatol. 2010;146(6):682-683. doi:10.1001/archdermatol.2010.128

Prurigo nodularis (PN) presents with excoriated nodules on the extensor surfaces of limbs and trunk. It is commonly seen in persons infected with human immunodeficiency virus (HIV) and with low CD4 counts.1 The pathogenesis of PN is not well understood, but it may be related to inflammatory mediators.24 Interestingly, combination therapy that includes raltegravir, an integrase inhibitor that prevents viral DNA insertion into host cell DNA, has been noted to rapidly reduce viral load to levels comparable to or lower than other HIV antiretroviral therapies (ARTs).5,6 We report 2 cases of PN that dramatically improved within 2 weeks of initiating twice daily oral dosing with raltegravir, 400 mg.

First Page Preview View Large
First page PDF preview
First page PDF preview